# A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

> **NCT04271475** · PHASE3 · TERMINATED · sponsor: **Actelion** · enrollment: 127 (actual)

## Conditions studied

- Chronic Thromboembolic Pulmonary Hypertension

## Interventions

- **DRUG:** Macitentan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04271475
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-07
- **Primary completion:** 2023-12-21
- **Final completion:** 2023-12-21
- **Target enrollment:** 127 (ACTUAL)
- **Why stopped:** The Sponsor decided to stop the study for futility based on a recommendation by the IDMC following a pre-planned interim analysis
- **Last updated:** 2025-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04271475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04271475, "A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04271475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*